Patents by Inventor Kenneth J. Sultzbaugh

Kenneth J. Sultzbaugh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180296479
    Abstract: A high dose orodispersible dosage form of oxcarbazepine is provided. Drug-containing particles of oxcarbazepine are included within a porous bound matrix. The dosage form disperses in saliva or water in less than 15 sec and it has sufficient hardness to withstand handling and storage. It can be used to treat diseases or disorders that are therapeutically responsive to oxcarbazepine or a derivative thereof.
    Type: Application
    Filed: June 22, 2018
    Publication date: October 18, 2018
    Applicant: APRECIA PHARMACEUTICALS LLC
    Inventors: Jules JACOB, Kelly CAPUTO, Micael GUILLOT, Kenneth J. SULTZBAUGH, Thomas G. WEST
  • Patent number: 10028909
    Abstract: A high dose orodispersible dosage form of oxcarbazepine is provided. Drug-containing particles of oxcarbazepine are included within a porous bound matrix. The dosage form disperses in saliva or water in less than 15 sec and it has sufficient hardness to withstand handling and storage. It can be used to treat diseases or disorders that are therapeutically responsive to oxcarbazepine or a derivative thereof.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: July 24, 2018
    Assignee: APRECIA PHARMACEUTICALS LLC
    Inventors: Jules Jacob, Kelly Caputo, Micael Guillot, Kenneth J. Sultzbaugh, Thomas G. West
  • Publication number: 20170172919
    Abstract: A high dose orodispersible dosage form of oxcarbazepine is provided. Drug-containing particles of oxcarbazepine are included within a porous bound matrix. The dosage form disperses in saliva or water in less than 15 sec and it has sufficient hardness to withstand handling and storage. It can be used to treat diseases or disorders that are therapeutically responsive to oxcarbazepine or a derivative thereof.
    Type: Application
    Filed: February 21, 2017
    Publication date: June 22, 2017
    Applicant: APRECIA PHARMACEUTICALS COMPANY
    Inventors: Jules JACOB, Kelly CAPUTO, Micael GUILLOT, Kenneth J. SULTZBAUGH, Thomas G. WEST
  • Patent number: 9616018
    Abstract: A high dose orodispersible dosage form of oxcarbazepine is provided. Drug-containing particles of oxcarbazepine are included within a porous bound matrix. The dosage form disperses in saliva or water in less than 15 sec and it has sufficient hardness to withstand handling and storage. It can be used to treat diseases or disorders that are therapeutically responsive to oxcarbazepine or a derivative thereof.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: April 11, 2017
    Assignee: Aprecia Pharmaceuticals Company
    Inventors: Jules Jacob, Kelly Caputo, Micael Guillot, Kenneth J. Sultzbaugh, Thomas G. West
  • Publication number: 20160250145
    Abstract: A high dose orodispersible dosage form of oxcarbazepine is provided. Drug-containing particles of oxcarbazepine are included within a porous bound matrix. The dosage form disperses in saliva or water in less than 15 sec and it has sufficient hardness to withstand handling and storage. It can be used to treat diseases or disorders that are therapeutically responsive to oxcarbazepine or a derivative thereof.
    Type: Application
    Filed: February 17, 2016
    Publication date: September 1, 2016
    Applicant: APRECIA PHARMACEUTICALS COMPANY
    Inventors: Jules JACOB, Kelly CAPUTO, Micael GUILLOT, Kenneth J. SULTZBAUGH, Thomas G. WEST
  • Patent number: 9314429
    Abstract: A high dose orodispersible dosage form of oxcarbazepine is provided. Drug-containing particles of oxcarbazepine are included within a porous bound matrix. The dosage form disperses in saliva or water in less than 15 sec and it has sufficient hardness to withstand handling and storage. It can be used to treat diseases or disorders that are therapeutically responsive to oxcarbazepine or a derivative thereof.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: April 19, 2016
    Assignee: APRECIA PHARMACEUTICALS COMPANY
    Inventors: Jules Jacob, Kelly Caputo, Micael Guillot, Kenneth J. Sultzbaugh, Thomas G. West
  • Publication number: 20150366802
    Abstract: A high dose orodispersible dosage form of oxcarbazepine is provided. Drug-containing particles of oxcarbazepine are included within a porous bound matrix. The dosage form disperses in saliva or water in less than 15 sec and it has sufficient hardness to withstand handling and storage. It can be used to treat diseases or disorders that are therapeutically responsive to oxcarbazepine or a derivative thereof.
    Type: Application
    Filed: August 27, 2015
    Publication date: December 24, 2015
    Applicant: APRECIA PHARMACEUTICALS COMPANY
    Inventors: Jules JACOB, Kelly CAPUTO, Micael GUILLOT, Kenneth J. SULTZBAUGH, Thomas G. WEST
  • Patent number: 5686113
    Abstract: An aqueous core microcapsule has a capsular wall provided with a peptide(s) of pre-determined binding specificity(ies) appended to the surface, the wall being the reaction product of an anionic polymer or salt thereof and a polyamine, salt thereof, mixtures thereof, or mixtures thereof with monoamines. The aqueous core may contain an active ingredient(s), and be targeted for delivery to specific cell tissues. The microcapsules are provided as a composition and in a kit with instructions for use in imaging, diagnosis, therapy, vaccination, and other applications.
    Type: Grant
    Filed: March 21, 1995
    Date of Patent: November 11, 1997
    Assignee: Temple University of the Commonwealth System of Higher Education
    Inventors: Tully J. Speaker, Kenneth J. Sultzbaugh